Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Researchers Give Update on Janus Kinase (JAK) Inhibitors

Kimberly Retzlaff  |  Issue: May 2020  |  

Kimberly Retzlaff is a freelance medical journalist based in Denver.

References

  1. Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016 May;75(5):831–841.
  2. Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all‐cause mortality in phase II, phase III, and long‐term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924–2937.
  3. Winthrop KL, Park S-H, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Jun;75(6):1133–1138.
  4. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Oct;66(10):2675–2684.
  5. Lilly. Baricitinib (LY3009104): Rheumatoid Arthritis (briefing document). NDA 207924. FDA Advisory Committee Meeting. 2018 Apr 23.
  6. Brown T. FDA warns of risk for PE, death with higher dose tofacitinib (Xeljanz) for RA. Medscape. 2019 Feb 25.

* Dr. Winthrop has received research funding from Pfizer and BMS; performed consultant work for Amgen, AbbVie, Pfizer, UCB, Genentech, BMS and Lilly; and serves on the data safety monitoring boards for RCTs conducted by UCB, Roche, Astellas, Lilly, Janssen and Galapagos.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Tips on Vaccinating Patients with Rheumatic Diseases

    CHICAGO—In October of last year, a 52-year-old woman came to see Kevin Winthrop, MD, MPH, associate professor in infectious diseases, public health and preventive medicine at the Oregon Health & Sciences University. She had rheumatoid arthritis and was taking methotrexate and prednisone. She had had little change in her RA disease severity and was considering…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Zoster Reactivation Risk in Patients Treated with Cyclophosphamide

    Varicella-zoster-virus (VZV) reactivation, which can cause patients to develop herpes zoster (i.e., shingles), occurs more frequently in patients with systemic vasculitis and systemic lupus erythematosus (SLE) who have received intravenous cyclophosphamide than in otherwise healthy adults, according to a retrospective study published in The Journal of Rheumatology by researchers in France.1 The study also shows…

    Herpes Zoster & Tofacitinib

    Shingles, also known as herpes zoster (HZ), is a common and sometimes debilitating disease that disproportionately affects elderly individuals and those who are immunocompromised. Patients with rheumatoid arthritis (RA) have a 1.5–2-fold higher risk of developing HZ compared with healthy adults. Treatment with some disease-modifying anti-rheumatic drugs (DMARDs) has been shown to increase this risk….